Cingulate Inc (nasdaq:CING) Share Price

Company Profile

Business description
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Contact
1901 West 47th Place
KansasKS66205
USA
T: +1 913 942-2300
https://www.cingulate.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14

Recommended

Strong demand for AI infrastructure drives fair value lift.

Roy Van Keulen | 30 September 2026

Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.

Morningstar | 28 September 2026

Trading at an 18% discount, this wide-moat stock is a rare find.

Malik Ahmed Khan, CFA | 22 September 2026

Index	Last price	Change	% Change
All Ordinaries	8,969.20	82.60	0.93%
CAC 40	7,964.51	71.36	-0.89%
DAX 40	25,199.19	200.02	-0.79%
Dow JONES (US)	50,906.05	443.87	-0.86%
FTSE 100	10,606.00	30.71	-0.29%
HKSE	24,613.27	89.70	0.37%
NASDAQ	26,861.06	63.52	0.24%
Nikkei 225	66,753.72	1,272.45	1.94%
NZX 50 Index	13,834.39	150.76	1.10%
S&P 500	7,651.54	19.30	-0.25%
S&P/ASX 200	8,789.30	80.00	0.92%
SSE Composite Index	3,842.19	11.74	0.31%